Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Long-Term Debt Repayments (2016 - 2023)

Historic Long-Term Debt Repayments for Avalo Therapeutics (AVTX) over the last 6 years, with Q3 2023 value amounting to $15.2 million.

  • Avalo Therapeutics' Long-Term Debt Repayments changed N/A to $15.2 million in Q3 2023 from the same period last year, while for Dec 2024 it was $15.2 million, marking a year-over-year increase of 338036.53%. This contributed to the annual value of $21.2 million for FY2023, which is N/A changed from last year.
  • Per Avalo Therapeutics' latest filing, its Long-Term Debt Repayments stood at $15.2 million for Q3 2023.
  • Over the past 5 years, Avalo Therapeutics' Long-Term Debt Repayments peaked at $15.2 million during Q3 2023, and registered a low of -$14.8 million during Q4 2022.
  • Its 3-year average for Long-Term Debt Repayments is $115690.0, with a median of $24342.0 in 2019.